DBP International AB and Vivo Biopharma LLC Enter into Asset Purchase and Collaboration agreements to Develop and Commercialize a novel Glioblastoma Treatment
Double Bond Pharmaceutical International AB (publ) (“DBP”) and Vivo Biopharma LLC (“Vivo”), a wholly owned subsidiary of Sauvie Inc. (“Sauvie”) today announced that they have entered into an asset purchase, collaboration and transition agreements for DBP’s SI-053 development product and related assets. SI-053 is a locally acting formulation of temozolomide for the treatment of glioblastoma and it received Orphan Drug Designation from the European Medicines Agency in 2016. Recently, SI-053 received both Competent Authority and Ethics Committee approvals to initiate a Phase 1 clinical trial